26 results about "Vaccine Potency" patented technology

Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.

An effective treatment method for a broad variety of diseases in both animals and humans is disclosed. The method includes combining one or more vaccines with a treatment compound to enhance vaccine efficacy. The disclosed treatment compound does not act directly on the pathogen, and thus the organisms cannot readily develop resistance to the treatment. When a compound such as, but not limited to, the disclosed compound is used in conjunction with one or more vaccines, a synergistic effect is realized. The suggested compound is derived from a lipopolysaccharide (LPS) of gram negative bacteria. The treatment compound is combined with one or more appropriate vaccines and is administered early in the life of an animal to achieve a synergistic effect compared with the use of the treatment compound or the vaccine alone.

Devices and methods are described for utilizing occlusive dressings in combination with topical medicaments to enhance the efficacy of vaccines. The occlusive dressing delivers a defined dose of a topical medicament that enhances the immune system responsiveness of the vaccine to the vaccination site and provides a barrier that maintains the topical medicament layer on the skin for a desired period of time while also providing a port through which the immunization composition can be administered. In some embodiments, the occlusive dressing comprises a wound dressing used to cover the injection site after vaccination.

The invention provides a construction method and application of a chicken fallopian tube embolism model, and belongs to the technical field of animal infection models. The invention provides a construction method of a chicken fallopian tube embolism model based on multi-pathogen infection. The mycoplasma synoviae, the infectious bronchitis virus and the riemerella anatipestifer are utilized to infect the chicken, and the clinical typical salpingemphasis pathological process including cheese-like substance accumulation in a salpingemphasis cavity, serious abdominal air sacculitis complications and related tissue inflammation changes can be accurately reproduced. The model constructed by the invention is high in morbidity, and is suitable for epidemic disease pathogenesis research, drug screening and vaccine potency test. Compared with an existing single pathogen infection model, the model is closer to a clinical reality multi-pathogen cooperative infection scene, and the blank of a standardized multi-pathogen mixed infection induced fallopian tube embolism animal model is filled up.

This invention relates to the field of biomedical technology, specifically to a stably expressed porcine pseudorabies virus gD recombinant protein, a vaccine composition, its preparation method, and its applications. The invention provides a stably expressed porcine pseudorabies virus gD recombinant protein, the amino acid sequence of which is shown in SEQ ID NO:7. The porcine pseudorabies virus gD recombinant protein is stably expressed in monoclonal cells, exhibiting stable expression levels after 48 consecutive passages. This lays a solid foundation for its subsequent applications in the preparation of stable porcine pseudorabies subunit vaccine compositions or in porcine pseudorabies virus vaccine efficacy testing formulations.

Provided herein are engineered T-celi receptors (TCRs) having nanomoiar affinity for the immuno-dominant pp65 peptide residing between residues 495-503 (NLV) in complex with HLA-A2*02:01. The TCRs may be membrane-hound TCRs, soluble TCRs, chimeric TCRs, or chimeric antigen receptors. Also provided are methods of using the engineered TCRs to treat diseases, monitor disease progression, monitor vaccine efficacy, and detecting NLV / A2 presentation on the surface of cells.

The invention provides a quantitative kit for a porcine epidemic diarrhea virus PEDV S protein. The quantitative detection of the PEDV S protein is realized by adopting an ELISA (Enzyme-Linked Immunosorbent Assay) method. The kit comprises a coated elisa plate, an HRP (horse radish peroxidase) labeled monoclonal antibody PEDV-mAb-002, a recombinant PEDV S protein standard substance, a substrate developing solution, a reaction stopping solution, a washing solution and a sample diluent auxiliary reagent. The kit is compared with a standard curve to accurately measure the content of PEDV S protein in a sample. The kit has high sensitivity and high specificity, can accurately detect PEDV S protein at low concentration, has no cross reaction, and ensures the application effect of the kit in actual samples. In performance verification, the kit shows good specificity, sensitivity, precision and correctness, and can meet rapid detection requirements. The kit is simple and convenient to operate, rapid in detection and accurate in result, is suitable for detecting the potency of the PEDV vaccine of the porcine epidemic diarrhea virus, and has relatively high application value and popularization prospect.

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to killer cell lectin-like receptor G1 (KLRG1). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes including treatment of cancers and to increase the effectiveness of vaccines.

Methods and systems for the multiple detection and / or measurement of biomarkers in a sample are provided herein. These methods and systems can be used for rapid disease detection and / or monitoring, monitoring of vaccine efficacy and immune response, monitoring of therapeutic agents, and / or monitoring of the safety and efficacy of treatments.

The invention provides a bivalent vaccine which comprises a rabbit hemorrhagic syndrome virus antigen, a rabbit hepatitis E virus antigen and a microbial freeze-dried slow-release agent, and provides a preparation method which comprises the following steps: culturing the rabbit hepatitis E virus by using passage cells, obtaining the rabbit hepatitis E virus antigen, inoculating the rabbit hemorrhagic syndrome virus, and carrying out freeze-drying on the rabbit hemorrhagic syndrome virus. A rabbit hemorrhagic syndrome virus antigen is obtained, the rabbit hemorrhagic syndrome virus antigen and a rabbit hepatitis E virus antigen are mixed in proportion, a freeze-drying protective agent is supplemented, and the bivalent vaccine is obtained. The invention further provides an application experiment result of the compound, and the compound is used for preventing or treating rabbit hemorrhagic syndrome and rabbit hepatitis E. According to the invention, the two antigens are proportioned properly, so that the prepared vaccine at least achieves the efficacy of preventing and controlling immune epidemic diseases. The bivalent vaccine provided by the invention can prevent two diseases by one injection, reduce immune stimulation, continuously enhance the immune effect of a body, promote the body to generate better immune response, reduce the immune cost, simplify the immune procedure, and is more economical and reliable.

The application belongs to the technical field of biotechnology and relates to the field of veterinary diagnosis, and particularly discloses a liquid-phase blocking ELISA kit for porcine Senecavirus neutralizing antibody, which contains porcine Senecavirus single-domain antibody and matched detection reagents, and the porcine Senecavirus single-domain antibody can also be an antigen-binding fragment of the single-domain antibody, the single-domain antibody is selected from one or more groups in 52 groups, the heavy chain variable region of each group of single-domain antibodies or antigen-binding fragments contains CDR-1, CDR-2 and CDR-3, the amino acid sequences of the heavy chain variable region CDR-1 (VH-CDR-1) of the 52 groups of single-domain antibodies or antigen-binding fragments are respectively shown in SEQ ID NO. 1-SEQ ID NO. 52, the amino acid sequences of the heavy chain variable region CDR-2 (VH-CDR-2) are respectively shown in SEQ ID NO. 53-SEQ ID NO. 104, and the amino acid sequences of the heavy chain variable region CDR-3 (VH-CDR-3) are respectively shown in SEQ ID NO. 105-SEQ ID NO. 156. The kit can quickly detect the SVA neutralizing antibody level in serum, has high sensitivity, good specificity and stable results, and can be better applied to SVA vaccine efficacy evaluation.

This invention belongs to the field of biotechnology, specifically relating to a hybridoma cell line secreting monoclonal antibodies against Clostridium perfringens ETX and its applications. Based on natural toxins, this invention establishes an indirect ELISA detection method using a non-toxic ETX single-amino acid site protein mutant. A series of hybridoma cell lines secreting monoclonal antibodies against Clostridium perfringens ETX were screened. These hybridoma cell lines can stably and efficiently secrete both neutralizing monoclonal antibodies and non-neutralizing monoclonal antibodies, and can be mass-produced on a large scale. This invention is the first to establish an antigen ELISA detection method for Clostridium perfringens ETX using monoclonal antibodies. This method features simple sample handling, low cost, rapid reaction, and high specificity. It can also provide a reference for the diagnosis of Clostridium perfringens infection and lay the foundation for research on alternative methods for testing the efficacy of related vaccines.

Aspects of the present disclosure relate to functionalized polymers and methods of use thereof. Certain aspects are directed to polymers comprising adjuvants for use in stimulating an immune response. In some cases, provided are polymers comprising inflammasome activators, in some cases also comprising a TLR agonist, which may be formulated in a pharmaceutical composition. Also disclosed are methods for improving vaccine efficacy and immunotherapy efficacy. Certain aspects relate to compositions and methods for stimulation of CD4+ and / or CD8+ T cell responses in a subject.

This invention discloses a vaccine potency prediction method based on a self-trained model, relating to the field of medical technology. The method constructs a prediction model by collecting spatiotemporal data such as time and temperature during the storage and distribution of vaccines, and continuously trains and optimizes the model parameters using historical data. The system includes data collection, cleaning, model training, and prediction display. This invention achieves rapid, non-destructive, and automated prediction of vaccine potency, improving the efficiency and safety of vaccine lifecycle management.

The inventors found that the overexpression of innate immune response and T cell exhaustion pathways is much more pronounced in pigs than in cattle, making pigs less likely than cattle to mount adaptive immune responses and humoral immune responses. This paper presents an innovative strategy to improve the abnormal immune responses in pigs by simultaneously inducing effective cellular and humoral immune responses and applying T cell agonists as new vaccine adjuvants. This result can provide important clues for understanding the differences in immune responses between cattle and pigs, while presenting a method for maximizing immune responses and vaccine efficacy, which are less expressed in pigs than in cattle.

A nucleic acid vaccine composition comprising one or more of a plasmid-based nucleic acid vaccine and immunotherapy, as well as a lipid formulation, is provided. In addition, the present invention provides a method of enhancing the potency of plasmid-based DNA vaccines and immunotherapies, by formulating a vaccine and / or immunotherapy in a lipid formulation, which is stable when refrigerated or stored frozen, is then delivered to a vaccinee by either needle / syringe, jet injection, or microneedles. The lipid formulation of the present invention comprises one or more lipid excipients selected from 1,2-Distearoyl-sn-glycero-3-phosphocholine, Cholest-5-en-3β-ol, 1,2-Dimyristoyl-rac-glycero-3-methylpolyoxyethlene, and or more symmetric ionizable cationic lipids. The present invention increases vaccine potency dramatically. It was unexpectedly discovered that the level of immunogen, or immune response molecules, produced in vivo is increased (versus administering merely the vaccine or immunotherapy) and, in the case of a vaccine immunogen, the immune response is enhanced.

The invention derives from the discovery that the immunogenicity of piscine orthoreovirus (PRV) can be significantly increased by inactivating the virus in a way different from the prior art: by incubation with an aziridine the vaccine potency against challenge infection by cohabitation is much improved over prior art approaches. This allowed the development of an effective inactivated vaccine against infection and disease caused by PRV.

According to the invention, a Chinese forest encephalitis virus inactivated vaccine is adopted to produce a strain'senzheng 'strain gene sequence, a structural protein preM-E gene sequence of the strain is amplified, an HIV-1 lentivirus packaging system is utilized, preM-E is used as a pseudovirus particle envelope protein, green fluorescent protein (EGFP) or luciferase reporter gene (Luciferae) is used as a detection indication signal to prepare the pseudovirus, and a BHK21 cell is used as a target cell; the pseudovirus-BHK21 cell system is used for replacing live virus operation experiments such as vaccine potency evaluation, neutralizing antibody detection (animal method or plaque reduction neutralization test) and the like, the biosafety operation environment is degraded from BSL-3 to BSL-2 by using pseudoviruses, the detection period is shortened, and animal experiments are reduced.

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to killer cell lectin-like receptor G1 (KLRG1). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes including treatment of cancers and to increase the effectiveness of vaccines.

The invention discloses a method for preparing a foot-and-mouth disease subunit recombinant protein vaccine and evaluating immune efficacy of the foot-and-mouth disease subunit recombinant protein vaccine. By optimizing the prokaryotic expression process of the O-type FMDV VP1 protein, the obtained recombinant VP1 protein is mainly expressed in the form of an inclusion body; an adjuvant compatibility scheme adaptive to the recombinant protein is further designed, so that the immunogenicity of the vaccine is enhanced; meanwhile, a mouse-based immune efficacy evaluation method is established, and low-cost and short-period vaccine efficacy evaluation is realized by detecting the immunogenicity of the VP1 protein. The method effectively solves the problems that the prokaryotic expression VP1 subunit vaccine is insufficient in immune efficacy and high in evaluation cost, and provides efficient and practical technical support for research, development and industrialization of foot-and-mouth disease subunit recombinant protein vaccines.

Compositions for determining the efficacy and / or potency of a vaccine preparation are described herein. Splenocytes from immunized animals are isolated and can be frozen. Upon thawing such cells are activated by exposure to a series of dilutions of a vaccine preparation being tested and a series of dilutions of a reference vaccine with known characteristics. Cells secreting immunogen-specific antibody and cells secreting nonspecific antibody are enumerated, as is the amount of immunogen-specific and nonspecific antibody produced. Comparison between the results from the vaccine preparations provides a measure of relative vaccine efficacy and / or potency.

Provided are a vaccine composition for Varicella Zoster virus (VZV) including a glycoprotein E (gE) antigen of VZV and monophosphoryl lipid A (MLA), and a method of using the same. The vaccine composition according to an aspect of the invention may significantly improve a production yield by including the gE antigen having an optimized signal peptide sequence, may enhance immunogenicity by including MLA, and may further enhance the immunogenicity enhanced by MLA by further adding saponin such as QS-21, and may be prepared in a form of CoPoP liposomes so that vaccine antigens may be presented on the surface of the liposomes for better absorption by antigen-presenting cells, and vaccine efficacy may be maximized by inclusion of the vaccine antigens and immune adjuvants in a formulation. Therefore, the vaccine composition may be useful as an alternative to current vaccines in the art for prevention or treatment of VZV infection.

The application discloses a specific goatpox virus P32 truncated protein and application thereof in vaccine efficacy detection. The amino acid sequence of the protein is shown as SEQ ID NO: 3. The specific truncated form (aa1-aa238) has significantly better soluble expression in E. coli than the full-length and other truncated forms (such as aa1-aa277). A competitive ELISA method for quantitatively detecting the efficacy of bovine nodular skin disease inactivated vaccine is established by taking the specific truncated form as a coating antigen. The method is systematically optimized, and has high sensitivity, strong specificity and good repeatability. Key is that the relative efficacy (RP) value measured by the method is highly correlated with animal challenge protection results, and when the RP value is greater than or equal to 1.0, complete immune protection can be predicted, so that the traditional animal challenge test can be reliably replaced. Compared with the immune challenge method, the detection period is greatly shortened (from 63 days to 2 days), target animals are not used, the detection cost is saved, and the method does not need P3 laboratory conditions and has no biosafety risk.

The invention discloses a non-antigen-dependent antibody rapid enhancement method and application, and relates to the technical field of biology. The method comprises the following steps: applying a non-antigen-dependent antibody rapid enhancer to an organism containing a pre-stored antibody in vivo so as to increase the content of the pre-stored antibody; the non-antigen-dependent antibody rapid enhancer comprises lipid nanoparticles coated with single-stranded oligonucleotide, the nucleotide sequence of the single-stranded oligonucleotide is as shown in SEQ ID NO. 1. According to the method, the level of the pre-stored antibody can be rapidly and remarkably improved in the body with the established immune memory under the condition that the exogenous antigen is completely not required to be stimulated again. The limitation that an existing antibody enhancement strategy must depend on antigens is broken through, and a brand-new technical tool and solution with wide application prospects are provided for quick awakening of vaccine efficacy, emergency enhancement of immune defense and controllable adjustment of in-vivo antibody level in antibody preparation.

Provided are compounds of formula (Ia), (Ib) and (IIa), and pharmaceutically acceptable salts thereof. Additionally provided are compositions and pharmaceutical compositions comprising the compounds, therapeutic methods using same for modulating (e.g., inhibiting) CREB binding protein (CBP) / β-catenin mediated signaling in treating a condition, disease or disorder (e.g., fibrosis, cancer, neurological conditions, metabolic disorders (e.g., diabetes, etc.), and skin conditions (dermatitis, psoriasis, scarring, alopecia, etc.) mediated by aberrant CBP / β-catenin signaling, and cosmetic methods for treating skin conditions (e.g., aging, etc.). Additionally, provided are methods for enhancing vaccine efficacy using the compounds and compositions. Further provided are methods for efficiently synthesizing a clinical grade drug, comprising use, in a penultimate, or last reaction step under GMP conditions, of an intermediate 2-propynyl-compound to form a clinical grade isoxazole derivative (e.g., via 3+2 cycloaddition).

The invention belongs to the technical field of biomedicine, and aims to solve the problems that virus gene mutation can generate new biological characteristics, so that the efficacy of an existing vaccine is reduced, and the condition of an infected pig is aggravated, a porcine reproductive and respiratory syndrome virus strain is obtained by utilizing Marc-145 and iPAM cell separation and identification, and the strain can be stably proliferated in the Marc-145 cell, so that the porcine reproductive and respiratory syndrome virus strain can be used for preparing a porcine reproductive and respiratory syndrome virus strain. The strain can be infected in immortalized swine alveolar macrophages, and has application potential as a vaccine candidate strain.